MedTrace Logo

Genomic Study of Relapse Esophageal Cancer After Radiotherapy

NCT04694391 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-01-26

No results posted yet for this study

Summary

Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. However, about half patients received radiotherapy occurred relapse. Once relapse occurred, there is no better treatment strategy. Genomic study of relapsed esophageal cancer is seldom. So the investigators attempt to collect relapsed tissue to conduct with whole exome sequencing in order to investigate the genome landscape of recurrence esophageal cancer.

Conditions

  • Gene Mutation-Related Cancer
  • Esophageal Cancer
  • Radiation Exposure

Interventions

GENETIC

whole exome sequence

To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Nantong University

    collaborator OTHER

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Ningbo No.2 Hospital

    collaborator OTHER

  • Taihe Hospital

    collaborator OTHER

  • Taian Cancer Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Kuaile Zhao, doctor · Fudan University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-14
Primary Completion
2020-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04694391 on ClinicalTrials.gov